MA44021B1 - Composés antitumoraux - Google Patents

Composés antitumoraux

Info

Publication number
MA44021B1
MA44021B1 MA44021A MA44021A MA44021B1 MA 44021 B1 MA44021 B1 MA 44021B1 MA 44021 A MA44021 A MA 44021A MA 44021 A MA44021 A MA 44021A MA 44021 B1 MA44021 B1 MA 44021B1
Authority
MA
Morocco
Prior art keywords
antitumor compounds
antitumor
compounds
cancer
compound
Prior art date
Application number
MA44021A
Other languages
English (en)
French (fr)
Other versions
MA44021A (fr
Inventor
Marchante María Del Carmen Cuevas
Solloso Andrés Francesch
Barrasa Valentín Martínez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MA44021A publication Critical patent/MA44021A/fr
Publication of MA44021B1 publication Critical patent/MA44021B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
MA44021A 2017-04-27 2018-04-27 Composés antitumoraux MA44021B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (2)

Publication Number Publication Date
MA44021A MA44021A (fr) 2019-05-15
MA44021B1 true MA44021B1 (fr) 2019-08-30

Family

ID=62063080

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44021A MA44021B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Country Status (37)

Country Link
US (5) US11332480B2 (zh)
EP (5) EP3615544B9 (zh)
JP (5) JP7186723B2 (zh)
KR (3) KR102492283B1 (zh)
CN (4) CN114736219B (zh)
AU (4) AU2018260314C1 (zh)
BR (1) BR112019022282A2 (zh)
CA (1) CA3061518A1 (zh)
CL (1) CL2019003057A1 (zh)
CO (1) CO2019011967A2 (zh)
CY (3) CY1121884T1 (zh)
DK (5) DK4101855T3 (zh)
EC (1) ECSP19083967A (zh)
ES (5) ES2741901T3 (zh)
FI (3) FI4101855T3 (zh)
HK (2) HK1255941B (zh)
HR (5) HRP20230455T1 (zh)
HU (5) HUE062032T2 (zh)
IL (3) IL289963B2 (zh)
JO (1) JOP20190254A1 (zh)
LT (5) LT4047002T (zh)
MA (2) MA44021B1 (zh)
MD (5) MD4047002T2 (zh)
ME (2) ME03466B (zh)
MX (3) MX2021016054A (zh)
MY (1) MY198004A (zh)
PH (1) PH12019550224A1 (zh)
PL (5) PL4101855T3 (zh)
PT (2) PT3395820T (zh)
RS (5) RS64200B1 (zh)
SG (2) SG10201913300YA (zh)
SI (5) SI3615544T1 (zh)
TN (2) TN2019000211A1 (zh)
TW (3) TW202344509A (zh)
UY (1) UY37706A (zh)
WO (1) WO2018197663A1 (zh)
ZA (1) ZA201907119B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CA3158733A1 (en) * 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
PE20230785A1 (es) 2020-04-21 2023-05-11 Pharma Mar Sa Conjugados de anticuerpos de farmacos
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
EP4340841A1 (en) 2021-05-19 2024-03-27 Pharma Mar S.A. Dosage regimens for ecubectedin
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
WO1986004062A1 (en) 1984-12-28 1986-07-17 Conpharm Ab Pharmaceutically active compound and a method for its preparation
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
DE3684868D1 (de) 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO1987007610A2 (en) 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
EP0358418B1 (en) 1988-09-05 1992-12-16 Sankyo Company Limited Cyclic peptide, its preparation and its use in the treatment of cardiovascular disorders
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
KR950702994A (ko) 1992-08-12 1995-08-23 로렌스 티. 웰츠 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
WO1998017275A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
DE69723728T2 (de) 1996-10-24 2004-06-03 The Board Of Trustees For The University Of Illinois, Urbana Totalsynthese des amino hip analogen von didemnin a
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
EP0981352B8 (en) 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO1999051238A1 (en) 1998-04-06 1999-10-14 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
AU759494B2 (en) 1998-05-05 2003-04-17 Pharma Mar S.A. Culture of sessile marine animals
JP4583598B2 (ja) 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ エクテイナシジン７４３の代謝産物
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
WO2001035974A2 (en) 1999-11-15 2001-05-25 Pharma Mar S.A. Aplidine treatment of cancers
US6686470B2 (en) 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
NZ521844A (en) 2000-04-07 2004-07-30 Univ Pennsylvania Tamandarin and didemnin analogs having deoxo-proline residue or dehydro-proline residue and methods of making and use thereof
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
BRPI0110024B8 (pt) 2000-04-12 2021-05-25 Pharma Mar Sa derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
MXPA02012121A (es) 2000-06-06 2003-06-06 Pharma Mar Sa Compuestos antitumorales.
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
KR100886161B1 (ko) 2000-07-11 2009-02-27 파르마 마르, 에스.에이. 항암제로서의 배리올린 유도체
EP2275175B1 (en) 2000-07-13 2016-08-24 ReCor Medical, Inc. Thermal treatment apparatus with ultrasonic energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
CZ2003993A3 (cs) 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
WO2002030441A2 (en) 2000-10-12 2002-04-18 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
ATE314084T1 (de) 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
IL155781A0 (en) 2000-11-06 2003-12-23 Pharma Mar Sa Effective antitumor treatments
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
JP2004521112A (ja) 2001-01-24 2004-07-15 メステックス アクチエンゲゼルシャフト 関節痛治療薬を製造することへの神経毒性物質の使用
RU2003126171A (ru) 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
US20050004012A1 (en) 2001-10-19 2005-01-06 Ramon Mangues Use of aplidine for the treatment of pancreatic cancer
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033012A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
JP4430009B2 (ja) 2002-10-18 2010-03-10 ファーマ・マール・エス・アー・ウー 新規な抗腫瘍化合物
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
EP1603584B1 (en) 2003-03-12 2008-08-27 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
JP2006519848A (ja) 2003-03-12 2006-08-31 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
MXPA05010064A (es) 2003-03-21 2006-05-17 Madeleine M Joullie Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
JP2006528611A (ja) 2003-07-25 2006-12-21 ノバルティス アクチエンゲゼルシャフト 置換ラクタムおよびそれらの抗がん剤としての使用
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
CA2540868A1 (en) 2003-10-09 2005-04-21 Abbott Laboratories Pyrrolidinyl urea derivatives as angiogenesis inhibitors
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US20080293725A1 (en) 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
BRPI0518250A2 (pt) 2004-10-26 2008-11-11 Pharma Mar Sa tratamentos anticÂncer
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
EP1879870A1 (en) 2005-05-03 2008-01-23 Pharma Mar, S.A. Antitumoral tetrahydro-pyrimidines
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
CN101278050A (zh) 2005-08-02 2008-10-01 马尔药品公司 参与噻可拉林生物合成的基因和噻可拉林的异源产生
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
ATE499098T1 (de) 2005-11-25 2011-03-15 Pharma Mar Sa Verwendung von parp-1-hemmern
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
KR101512503B1 (ko) 2006-02-28 2015-04-15 파르마 마르 에스.에이. 개선된 항종양 치료
CA2652035A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
CN102336730A (zh) 2006-06-16 2012-02-01 马尔药品公司 抗肿瘤二羟基吡喃-2-酮化合物
US20100267732A1 (en) 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
NZ584695A (en) 2007-10-19 2011-06-30 Pharma Mar Sa Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)
JP2011500650A (ja) 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
US8748388B2 (en) 2007-12-14 2014-06-10 Pharma Mar, S.A. Antitumoral compounds
RS52343B (en) 2007-12-20 2012-12-31 Pharma Mar S.A. ANTITUMOR UNITS
EP2252315A1 (en) 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
JP2011513429A (ja) 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗癌治療法
CA2717117A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
NZ589269A (en) 2008-05-16 2013-03-28 Pharma Mar Sa Combination therapy with an antitumor alkaloid
US8435992B2 (en) 2008-05-16 2013-05-07 Pharma Mar S.A. Multiple myeloma treatments
NZ588526A (en) 2008-05-23 2012-08-31 Wyeth Llc Triazine compounds as pi3 kinase and mtor inhibitors
CN102083840A (zh) 2008-07-03 2011-06-01 马尔药品公司 抗肿瘤大环内酯类化合物
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
KR20110043681A (ko) 2008-07-17 2011-04-27 파르마 마르 에스.에이. 항암 화합물
NZ593169A (en) 2008-12-19 2013-07-26 Pharma Mar Sa Anticancer compounds
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
AU2011247634B2 (en) 2010-04-27 2016-07-07 Pharma Mar, S.A. Anticancer steroidal lactones unsaturated in position 7 (8)
CN107033164A (zh) * 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
KR20170096224A (ko) 2010-11-12 2017-08-23 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
KR20190026902A (ko) 2016-07-14 2019-03-13 화이자 인코포레이티드 바닌-1 효소의 억제제로서의 신규 피리미딘 카르복스아미드
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
WO2018197663A1 (en) 2018-11-01
KR102491180B1 (ko) 2023-01-20
CN110621678A (zh) 2019-12-27
AU2022200250C1 (en) 2022-06-23
CO2019011967A2 (es) 2020-02-18
JP6501946B2 (ja) 2019-04-17
RS64174B1 (sr) 2023-05-31
MY198004A (en) 2023-07-25
ES2741901T3 (es) 2020-02-12
CN110621678B (zh) 2024-09-20
TW202202509A (zh) 2022-01-16
CN114736219A (zh) 2022-07-12
IL270153A (zh) 2019-12-31
AU2018260314C1 (en) 2022-04-21
CY1121884T1 (el) 2020-10-14
JP6501947B2 (ja) 2019-04-17
DK3395820T3 (da) 2019-08-12
HRP20231233T1 (hr) 2024-01-19
ES2944344T3 (es) 2023-06-20
EP4101855B1 (en) 2023-08-02
KR102492283B1 (ko) 2023-01-27
IL289963B1 (en) 2023-06-01
US20180312529A1 (en) 2018-11-01
KR20220109495A (ko) 2022-08-04
SI3395820T1 (sl) 2019-09-30
CN114736219B (zh) 2024-06-07
LT3615544T (lt) 2023-05-10
PT3395820T (pt) 2019-08-07
US20210246146A1 (en) 2021-08-12
ZA201907119B (en) 2021-07-28
TW202344509A (zh) 2023-11-16
JP2018188431A (ja) 2018-11-29
PL4047002T3 (pl) 2023-07-24
IL289963A (en) 2022-03-01
ME03466B (me) 2020-01-20
RS59173B1 (sr) 2019-10-31
MD4047002T2 (ro) 2023-08-31
HUE046109T2 (hu) 2020-02-28
HK1255941B (zh) 2020-04-29
JP2018188432A (ja) 2018-11-29
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
FI3615544T3 (fi) 2023-05-23
TN2019000211A1 (en) 2021-01-07
HK1255938B (zh) 2020-04-29
HRP20191442T1 (hr) 2019-11-15
US11332480B2 (en) 2022-05-17
ES2740073T3 (es) 2020-02-05
MX2021016054A (es) 2022-06-01
JP2023052597A (ja) 2023-04-11
CN114751920B (zh) 2024-06-07
DK3615544T3 (da) 2023-05-30
PT3395821T (pt) 2019-08-27
TN2019000210A1 (en) 2021-01-07
EP3395821B1 (en) 2019-05-15
ME03467B (me) 2020-01-20
PH12019550224A1 (en) 2020-10-12
BR112019022282A2 (pt) 2020-05-19
IL295044A (en) 2022-09-01
DK3395821T3 (da) 2019-08-19
CL2019003057A1 (es) 2020-02-21
CY1121885T1 (el) 2020-10-14
MD3395820T2 (ro) 2019-10-31
EP4101855A1 (en) 2022-12-14
IL295044B1 (en) 2023-07-01
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
TWI807411B (zh) 2023-07-01
AU2018260314A1 (en) 2019-10-31
JP7186723B2 (ja) 2022-12-09
EP4101855B9 (en) 2024-01-03
US20220242883A1 (en) 2022-08-04
RS59174B1 (sr) 2019-10-31
EP3615544B1 (en) 2023-03-22
US10538535B2 (en) 2020-01-21
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
LT3395820T (lt) 2019-08-12
ECSP19083967A (es) 2019-12-27
KR20200012846A (ko) 2020-02-05
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
AU2022201657A1 (en) 2022-03-31
RS64200B1 (sr) 2023-06-30
SI3395821T1 (sl) 2019-09-30
HUE062157T2 (hu) 2023-10-28
US20210070775A1 (en) 2021-03-11
CY1126061T1 (el) 2023-11-15
CA3061518A1 (en) 2018-11-01
HUE063736T2 (hu) 2024-01-28
KR102510975B1 (ko) 2023-03-16
MX2021016058A (es) 2022-02-03
SG10201913300YA (en) 2020-03-30
MA44020A (fr) 2018-10-31
PL3615544T3 (pl) 2023-07-17
EP3395820A1 (en) 2018-10-31
JP2022130682A (ja) 2022-09-06
MA44021A (fr) 2019-05-15
AU2022200250B1 (en) 2022-02-10
LT4101855T (lt) 2023-08-25
LT4047002T (lt) 2023-05-10
TWI742273B (zh) 2021-10-11
SI4101855T1 (sl) 2024-03-29
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
LT3395821T (lt) 2019-08-12
IL289963B2 (en) 2023-10-01
RS64686B1 (sr) 2023-11-30
AU2018260314B2 (en) 2021-12-09
JP2020517709A (ja) 2020-06-18
UY37706A (es) 2018-11-30
AU2022200249B1 (en) 2022-02-10
MD3615544T2 (ro) 2023-08-31
MX2019012812A (es) 2020-01-14
SG11201909841RA (en) 2019-11-28
EP3615544A1 (en) 2020-03-04
US11713325B2 (en) 2023-08-01
PL3395821T3 (pl) 2019-10-31
FI4047002T3 (fi) 2023-05-22
ES2960063T3 (es) 2024-02-29
HUE062032T2 (hu) 2023-09-28
EP3395821A1 (en) 2018-10-31
ES2944579T3 (es) 2023-06-22
HRP20191443T1 (hr) 2019-11-15
EP4047002B1 (en) 2023-03-08
HUE045641T2 (hu) 2020-01-28
CN117865987A (zh) 2024-04-12
JP7422812B2 (ja) 2024-01-26
HRP20230433T1 (hr) 2023-07-07
IL295044B2 (en) 2023-11-01
EP3395820B1 (en) 2019-05-15
JP7490835B2 (ja) 2024-05-27
IL270153B2 (en) 2023-10-01
DK4101855T3 (da) 2023-11-06
FI4101855T3 (fi) 2023-09-22
IL270153B1 (en) 2023-06-01
JOP20190254A1 (ar) 2019-10-27
EP4047002A1 (en) 2022-08-24
HRP20230455T1 (hr) 2023-07-21
KR20210126791A (ko) 2021-10-20
SI3615544T1 (sl) 2023-07-31
TW201906850A (zh) 2019-02-16
EP3615544B9 (en) 2024-01-03
DK4047002T3 (da) 2023-05-01

Similar Documents

Publication Publication Date Title
MA44021B1 (fr) Composés antitumoraux
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
MA46337A (fr) Composé de pyridine
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
MA38039A1 (fr) Composés de céphem substitués en position 2
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA40221A (fr) Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale
FR3066761B1 (fr) Nouveaux composes inhibiteurs des canaux ioniques
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39305A3 (fr) Dérivés d'éthynyle
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
FR3020809B1 (fr) Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique
MA48455B1 (fr) Composés antitumoraux
MA39529B1 (fr) Agent stabilisant hautement efficace
MA20150280A2 (fr) Dérivés d'aryléthynyle
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
EA201891987A1 (ru) Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она
FR3062796B1 (fr) Utilisation d'un compose appartenant a la famillle des diuretiques pour traiter le cancer